Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2015

View Archived Issues

Gene Techno Science grants exclusive rights to Mochida for codevelopment of biosimilars

Development of a chimeric IL-1R antagonist that is activated in vivo during inflammation

Discovery and preclinical development of a MCH-R1 antagonist candidate for weight control

Clovis Oncology enters into trial collaboration with Genentech

Development of a second-generation utrophin modulator for the treatment of DMD

G1 initiates two phase Ib/IIa trials of G1T28 for SCLC

Novartis studies MCS-110 in phase II trial for triple negative breast cancer

CNFT gene therapy protects cone photoreceptors in a mouse model of retinitis pigmentosa

Sorrento Therapeutics announces new acquisitions and agreements

Neuropore announces phase I trials of NPT200-11 for the treatment of Parkinson's disease

FDA accepts NDA filing for SD-809 for Huntington disease

Phase II study of venetoclax meets primary endpoint

PsychoGenics licenses new alpha-synuclein transgenic mouse model from UCSD

Codexis signs agreement for use of CodeEvolver technology

Ceftobiprole receives FDA QIDP designation for lung and skin infections

Poseida and Janssen agree to use Centyrins in the development of CAR therapies

Cytos Biotechnology licenses CYT-003 and VLP platform to Checkmate Pharmaceuticals

CMC Biologics to develop and manufacture MAbs for PATH Malaria Vaccine Initiative

NIDA grant supports Southern Research's work on opioid drugs

Midatech and Ophthotech sign agreement to explore sustained delivery formulations

Merck & Co. discloses beta-lactamase inhibitors

Roche patents muscarinic M1 PAMs

Jiangsu Carefree Pharmaceutical introduces JAK inhibitors

AlphaBeta divulges Abeta neurotoxicity inhibitors

Daiichi Sankyo discloses compounds for hyperphosphatemia

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...